Host RNA-binding proteins as broad-spectrum targets for antiviral therapy
Abstract
Abstract RNA-binding proteins (RBPs) regulate key host processes and facilitate viral replication. Certain antiviral RBPs limit infection and trigger immune responses. Targeting these proteins could yield broad-spectrum antiviral activity with a lower risk of resistance. Nonetheless, translating this approach into clinical use requires balancing antiviral activity with the preservation of essential host functions. This review explores current RBP-directed antivirals and considers key challenges and future research directions.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.